113 related articles for article (PubMed ID: 29288559)
1. Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
Eur J Haematol; 2018 Apr; 100(4):367-371. PubMed ID: 29288559
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
3. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
[TBL] [Abstract][Full Text] [Related]
4. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
5. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
7. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
8. Transient presence of clonal chromosomal aberrations in Ph-negative cells in patients with chronic myeloid leukemia remaining in deep molecular response on tyrosine kinase inhibitor treatment.
Gniot M; Lewandowski K; Ratajczak B; Lewandowska M; Lehmann-Kopydłowska A; Jarmuż-Szymczak M; Komarnicki M
Cancer Genet; 2014; 207(10-12):503-10. PubMed ID: 25496750
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Visser O; Cornelissen JJ; Westerweel PE
Haematologica; 2017 Nov; 102(11):1842-1849. PubMed ID: 28860339
[TBL] [Abstract][Full Text] [Related]
10. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays.
Bennour A; Saad A; Sennana H
Crit Rev Oncol Hematol; 2016 Jan; 97():263-74. PubMed ID: 26412717
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
Talwar R; Choudhry VP; Jobanputra V; Kucheria K
Natl Med J India; 2002; 15(4):195-8. PubMed ID: 12296472
[TBL] [Abstract][Full Text] [Related]
13. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
14. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
15. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
16. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
17. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
Stock W; Westbrook CA; Peterson B; Arthur DC; Szatrowski TP; Silver RT; Sher DA; Wu D; Le Beau MM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 Jan; 15(1):26-36. PubMed ID: 8996121
[TBL] [Abstract][Full Text] [Related]
18. Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
Etienne G; Huguet F; Guerci-Bresler A; Nicolini FE; Maloisel F; Coiteux V; Dauriac C; Carpentier N; Bourdeix I; Tulliez M; Cony-Makhoul P
Br J Haematol; 2016 Jul; 174(1):71-80. PubMed ID: 27060881
[TBL] [Abstract][Full Text] [Related]
19. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B; Fioretos T; Mitelman F
Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
